CVS Health to Split Pharmacy and Insurance Businesses in Major Restructuring

CVS Health plans to separate its retail pharmacy operations from its health insurance, pharmacy benefit management and healthcare services businesses, unwinding a vertically integrated healthcare group with a reported market value of approximately $117 billion. The proposed restructuring will create two independent, publicly traded companies, with completion targeted for the first half of 2028.

Announced on 4 November 2026, the separation will divide the US healthcare company’s operations into a healthcare solutions business and a retail pharmacy and community healthcare business. Existing shareholders are expected to own shares in both companies following the transaction.

The announcement triggered a sharp market reaction. CVS Health shares closed 12.5% lower at $79.96 on 4 November, reducing the company’s market capitalisation by nearly $15 billion, according to Reuters.

The planned separation follows a strategic review by the company’s board and comes amid increasing scrutiny of vertically integrated healthcare business models in the United States.

CVS Health separation will create two independent companies

The restructuring will divide CVS Health’s operations into two businesses with distinct commercial activities.

The first company will retain the healthcare solutions operations, including Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health. These businesses cover health insurance, pharmacy benefit management, specialty pharmacy and healthcare delivery services.

The second company, which will operate under the name CVS Pharmacy, will include approximately 9,000 retail pharmacies, mail pharmacy operations, MinuteClinic locations, virtual care services and the Health100 technology services business.

CVS Health said the proposed separation is intended to give both organisations greater operational focus and flexibility to pursue their respective growth strategies.

David Joyner, currently chairman and chief executive of CVS Health, is expected to lead the healthcare solutions company. Prem Shah, the company’s current group president, is expected to become chief executive of CVS Pharmacy.

The separation is intended to be tax-free to CVS Health and its shareholders, subject to the applicable requirements and approvals.

Completion targeted for the first half of 2028

CVS Health expects to complete the transaction during the first half of 2028.

The company will need to undertake the necessary corporate, regulatory and operational preparations to establish both businesses as independent publicly traded entities.

The separation remains subject to customary conditions, including final board approval, an effective registration statement with the US Securities and Exchange Commission and confirmation of the intended tax treatment.

CVS Health has also indicated that both companies are expected to maintain investment-grade credit ratings, generate strong free cash flow and retain flexibility for strategic capital deployment.

Existing shareholders are expected to receive ownership interests in both businesses when the separation is completed. The final capital structures and other financial arrangements will be important considerations as the process advances.

Regulatory scrutiny increases pressure on integrated healthcare models

The proposed breakup comes after years of consolidation across the US healthcare sector.

CVS Health expanded its operations through acquisitions that brought retail pharmacies, health insurance and pharmacy benefit management under a single corporate structure. Its acquisition of Caremark in 2007 was a major step towards integrating pharmacy services with its broader healthcare operations.

However, vertical integration has attracted increasing criticism from regulators, healthcare customers and industry participants over potential conflicts of interest and its impact on healthcare costs.

CVS has significant exposure to this business model because its operations span insurers, pharmacies and pharmacy benefit management services.

Morningstar analyst Julie Utterback said management may have considered a proactive separation preferable to waiting for a regulatory or legislative decision that could force changes to the business structure.

The proposed restructuring therefore represents a significant response to the changing regulatory and commercial environment surrounding US healthcare companies.

2027 earnings outlook raises investor concerns

Despite reporting stronger third-quarter operating results, CVS faces questions over its earnings outlook for 2027.

The company forecast adjusted earnings per share of at least $8.65 for 2027, compared with analysts’ average estimate of $8.53, according to the Reuters report.

However, investors expressed concerns about the outlook for its pharmacy benefit management business, including the impact of a government drug discount pricing programme, a less robust customer selling season and declining membership in health plans.

Chief Financial Officer Brian Newman highlighted these challenges during the company’s earnings call.

Kevin Gade, chief operating officer at Bahl & Gaynor, said the forecast appeared less attractive relative to some competitors that were expected to deliver stronger earnings growth.

The earnings outlook added another consideration for investors assessing the proposed corporate separation and its potential financial benefits.

Third-quarter results show improvement across key operations

CVS Health reported adjusted earnings of $2.09 per share for the third quarter of 2026, exceeding analysts’ average estimate of $1.65, according to LSEG data cited by Reuters.

The company also reported third-quarter revenue of $108.4 billion, representing a 5.4% increase from the corresponding period a year earlier.

Its adjusted earnings per share increased from $1.60 in the third quarter of 2025. CVS also raised its full-year 2026 adjusted earnings guidance to at least $8.20.

Chief Executive David Joyner said the company’s pharmacy, insurance and healthcare services businesses had made considerable operational progress over the preceding two years.

Nevertheless, investors remain focused on how the separation will affect the financial performance, costs and competitive positioning of the two businesses.

CVS breakup could reshape competition across the healthcare value chain

The planned separation has implications beyond CVS Health itself.

For retail pharmacy operators, the creation of an independent CVS Pharmacy could change how the company approaches store operations, prescription fulfilment, community healthcare services and investment.

The healthcare solutions company will retain Aetna and Caremark, keeping health insurance and pharmacy benefit management operations together with specialty pharmacy and care delivery businesses.

Pharmaceutical manufacturers, healthcare providers, pharmacy suppliers and other service companies will be watching how the restructuring affects commercial relationships and procurement arrangements.

The separation also comes as regulators continue to examine the role of pharmacy benefit managers and the broader structure of the US prescription drug market.

For CVS, the challenge will be to establish two financially sustainable companies while managing separation costs, operational dependencies and potential changes in commercial relationships.

What to watch as CVS prepares for separation

The first half of 2028 remains the company’s target for completing the restructuring. Before then, investors and healthcare industry participants will be monitoring the final capital structures, regulatory requirements, separation costs and financial performance of the businesses.

The ability of both companies to operate independently while maintaining investment-grade credit ratings and strong cash generation will be central to the success of the transaction.

The proposed breakup marks a major change in CVS Health’s corporate structure and adds to a broader trend of large companies reassessing vertically integrated business models amid regulatory and competitive pressures.

Follow B2B Market Signal on social media for the latest business news, industry developments, market intelligence and analysis. Connect with us on LinkedIn and follow us on Instagram at @b2bmarketsignal for regular updates